South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, March 16, 2018
1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Kelley Oehlke, PharmD	X
Dana Darger, RPh		Lenny Petrik, PharmD	
James Engelbrecht, MD		Timothy Soundy, MD	
Mikal Holland, MD		Mike Jockheck, DSS Staff	X
Richard Holm, MD	X	Sarah Aker, DSS Staff	X
Bill Ladwig, RPh, Chair	X	Mary Carpenter, MD, DSS Staff	X

Administrative Business

The meeting was called to order by Ladwig at 1:06 PM. The minutes of the December meeting were presented. Holm made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report for November 13, 2017 through December 30, 2017. There were a total of 776 PAs reviewed during this time period. There were 342 requests (44%) received via telephone and 434 requests (56%) received via fax.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from 10/1/2017 to 12/31/2017. The top five classes were atypical antipsychotics, insulins, respiratory and CNS stimulants, amphetamines, and anticonvulsants. The top 15 therapeutic classes make up 31.97% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 17.40% of total claims. Cystic fibrosis potentiators dropped from the top 15 therapeutic classes by total cost of claims during this quarter.

Peer-to-peer update

Jockheck provided a peer-to-peer update on prescribers with recipients utilizing opioids greater than 300 MED. Of the top ten patients; three recipients had a terminal diagnosis and two had started on a tapering schedule. For the remaining five recipients, their records were still under review to assemble a plan of action.

Review of Duzallo & Zurampic

The committee reviewed Duzallo and Zurampic clinical information and requested utilization summary of all anti-gout agents for the next meeting. In addition, committee was made aware of a drug safety communication from the FDA regarding increased risk of heart-related death with febuxostat. There was no public comment.

Review of PA Forms & Criteria

The committee reviewed all PA criteria currently in effect and requested follow up information for a more in-depth review at the next meeting:

- Non-Sedating Antihistamines – under consideration for PA removal; requested PA approval/denial information (page 33)
- Non-Sedating Antihistamines (chewable, liquid, ODT) – under consideration for PA removal; requested PA approval/denial and cost information (page 34)
- Amrix & Fexmid (cyclobenzaprine) – Committee requested utilization and PA summary (page 37)
- Genitourinary Smooth Muscle Relaxant – Holm commented on its questionable benefit and potential danger; and questioned whether criteria should these be strengthened (page 45)
- Hepatitis C – Mavyret and Vosevi are being added to criteria (page 55)
- Immunomodulator – add Kevzara to criteria (pages 64-81)
- Topical Ketoconazole – Committee inquired if a PA was warranted; under consideration for PA removal if drugs are now inexpensive (page 82)
- Topical Onychomycosis Agents – under consideration for PA removal if inexpensive (page 83)
- Lidoderm – Committee requested utilization, PA approval/denial, and cost (page 87)
- Nasal Steroids – under consideration for PA removal if inexpensive; Committee commented on many of the products' OTC status; requested utilization and pricing information (page 94)
- Topical Acne Agents – Committee requested to make sure only brand products on PA; utilization data and PA information requested (page 103)
- Proton Pump Inhibitors – Committee requested utilization of PPIs including PA approval/denial information (page 107)
- Soma 250 mg – Committee requested utilization for all soma products (page 113)
- Tramadol ER – Committee requested all tramadol utilization (page 115-116)

Pipeline & Patent Expiration
Pipeline and patent information for 1Q18 were reviewed.

FDA Advisory Committee – opioids c/c in children
Committee reviewed the FDA Pediatric Advisory Committee recommendations on the benefit/risk profile on the use of prescription opioid cough suppressants for treatment of cough in patients under 18 years of age. After reviewing utilization data of all cough/cold/allergy for recipients under 18 years old for South Dakota Medicaid recipients, committee inquired what the other State Medicaid plans are doing regarding these FDA recommendations. Committee requested a PA form be developed to review at the next meeting. Baack volunteered to provide feedback on proposed PA criteria prior to the next meeting.

Review of Ingrezza
Ingrezza clinical information was presented for review. Thom Board, representative from Neurocrine Biosciences, spoke and provided additional information highlighting the AIMS score for primary endpoint for Ingrezza. He also mentioned that utilization was mainly within the dual eligible population. Committee wanted to monitor utilization for the next meeting.

Review of Xepi
Xepi clinical information was presented for review. Committee recommended adding Xepi to step therapy with a 10 day trial of mupirocin ointment first within the last 3 months. Holm motioned adding Xepi to PA. Baack seconded the motion. The motion was approved unanimously.

Next meeting is scheduled for 6/15/2018. Meeting dates of 9/7/2018 and 12/7/2018 were also scheduled. Baack made a motion to adjourn. Holm seconded. The meeting adjourned at 3:18 PM.